{"id":"NCT02406092","sponsor":"Hoffmann-La Roche","briefTitle":"Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A","officialTitle":"An Open-Label, Multinational, Multicenter, Phase IIIB Study to Assess Safety of Rituximab Following Subcutaneous Administration in Patients With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-13","primaryCompletion":"2021-06-30","completion":"2021-06-30","firstPosted":"2015-04-02","resultsPosted":"2024-11-21","lastUpdate":"2024-11-21"},"enrollment":139,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Hodgkin Lymphoma"],"interventions":[{"type":"DRUG","name":"Rituximab","otherNames":["MabTheraÂ®"]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":["Endoxan"]},{"type":"DRUG","name":"Doxorubicin","otherNames":[]},{"type":"DRUG","name":"Vincristine","otherNames":[]},{"type":"DRUG","name":"Prednisone","otherNames":[]},{"type":"DRUG","name":"Fludarabine","otherNames":[]}],"arms":[{"label":"Rituximab","type":"EXPERIMENTAL"}],"summary":"This open-label, single-arm study will evaluate the safety of rituximab subcutaneously (SC) administered during first line treatment for follicular non-Hodgkin's lymphoma (NHL) (Induction and/or Maintenance treatment plus 24 months of follow up), or diffuse large B-cell lymphoma (DLBCL) (treatment plus 24 months of follow-up).","primaryOutcome":{"measure":"Percentage of Participants With Administration-Associated Reactions (AARs)","timeFrame":"Within 24 hours of each rituximab SC administration (maximum treatment duration up to 32 months for FL participants and up to 8 months for DLBCL participants)","effectByArm":[{"arm":"DLBCL Arm","deltaMin":1.1,"sd":null},{"arm":"FL Arm","deltaMin":3.7,"sd":null},{"arm":"Overall Population","deltaMin":1.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":13,"countries":["Algeria","Morocco","Tunisia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":95},"commonTop":["Neutropenia","Paraesthesia","Anaemia","Mucosal Inflammation","Leukopenia"]}}